Tom McCourt joined Ironwood in 2009. Mr. McCourt has served as the chief executive officer and member of the board of directors since June 2021 and has served as president and interim chief executive officer from February 2021 to June 2021. Mr. McCourt had served as president from April 2019 to June 2021. Prior to April 2019, Mr. McCourt had served as our senior vice president of marketing and sales and chief commercial officer since joining Ironwood in 2009.

Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from April 2008 to August 2009. Prior to that, Mr. McCourt was with Novartis AG from 2001 to 2008, where he directed the launch and growth of ZELNORM™ for the treatment of patients with IBS-C and CIC and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager for PRILOSEC® and NEXIUM®.

Mr. McCourt serves on the board of directors and as a member of the compensation committee of Pliant Therapeutics, Inc. (Nasdaq: PLRX) and on the board of trustees for the American Society of Gastrointestinal Endoscopy (ASGE). Mr. McCourt recently served on the board of directors of Acceleron Pharma Inc., serving as Chairman of the Nomination and Governance committee and as a member of the Audit and Compensation committees.

Mr. McCourt holds a degree in pharmacy from the University of Wisconsin.